The $241,944 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under its Biomedical Research and Research Training program (CFDA 93.859) supports research on the pharmacological potential of combined translation and autophagy inhibition for treating high-grade serous ovarian cancer (HGSOC). The project aims to study the efficacy and mechanisms of two novel natural product compounds, didesmethylrocaglamide (DDR) and phyllanthusmin34 (PHY34), which inhibit mRNA translation and autophagy, respectively, as a potential combination therapy for HGSOC. Key activities include testing the combinatorial effects of DDR and PHY34 on tumor burden in animal models, as well as determining the mechanism of action through proteomic analysis. The research will be conducted by the University of Illinois from August 2024 through July 2026.
Generated 2/25/25, 4:16 AM